In recent years, China’s pharmaceutical regulation has increasingly aligned with global standards, fostering an environment conducive to the industry’s high-quality development. The internationalization of China’s pharmaceutical industry, encompassing trade, investment, overseas clinical trials, and licensing transactions, has advanced steadily. However, as the international political and economic landscape continues to evolve, the global development pattern of the healthcare industry also faces profound adjustments and transformations. Developing regulatory science for pharmaceutical innovation and internationalization is an important approach commonly adopted by the government, industry, and academia. Against this backdrop, to further develop and adopt regulatory science for promoting pharmaceutical innovation and internationalization in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA), this conference aims to facilitate exchange ideas and collaborations among experts and professionals across regulatory authorities, industry, academia, contributing insights and efforts to the development of regulatory science for the pharmaceutical innovation in the GBA.